Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the interim CEO and will remain as an advisor to the company.
Sanna joins Semma from Magenta Therapeutics, where he served as chief operating officer. Prior to Magenta, he served in a leadership team of Novartis' cell and gene therapy unit as the global program head of stem cell transplant and early programs.
In an earlier role, he served as global head of strategic planning and portfolio management at the Novartis Institutes for BioMedical Research.
Semma Therapeutics is pioneering the curative use of stem cells in regenerative medicine by coupling its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system.
Its ongoing research is focused on combining these highly-differentiated active cells with a state-of-the-art device to provide a functional cure for patients with diabetes. Geadquartered in Cambridge, MA, the company has operations in Providence, RI.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project